A hitchhiker's guide to antisense and nonantisense biochemical pathways

Hepatology

Volumn 24, Issue 6, 1996, Pages 1517-1529

  Branch, Andrea D ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; OLIGODEOXYNUCLEOTIDE; RIBONUCLEASE H; RIBOZYME;

GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; NUCLEIC ACID PROBE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RNA BINDING; REVIEW; RNA RNA HYBRIDIZATION; SILENT GENE;

EID: 0029979731     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008938189     Document Type: Article

References (136)

1. Izant JG, Weintraub H. Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 1984; 36:1007-1015.
2. Izant JG, Weintraub H. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science 1985;229:345-352.
3. Harland R, Weintraub H. Translation of mRNA injected into Xenopus oocytes is specifically inhibited by antisense RNA. J Cell Biol 1985;101: 1094-1099.
4. Weintraub HM. Antisense RNA and DNA. Sci Am 1990;262:40-46.
5. Askari FK, McDonnell WM. Molecular medicine: antisense-oligonucleotide therapy. N Engl J Med 1996;334:316-318.
6. Uhlmann E, Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chemical Reviews 1990;90:544-584.
7. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992;32:329-376.
8. Agrawal S. Antisense oligonucleotides as antiviral agents. Trends Biotechnol 1992;10:152-158.
9. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993;261:1004-1012.
10. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994;372:333-335.
11. Chang AG, Wu GY. Gene therapy: applications to the treatment of gastrointestinal and liver diseases. Gastroenterology 1994;106:1076-1084.
12. Offensperger W-B, Blum HE, Cerok W. Therapy of hepadnavirus infection using antisense oligonucleotides. Intervirology 1995;38:113-119.
13. Gura T. Anti Sense has growing pains. Science 1995;270:575-577.
14. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. TIBTECH 1996;14:147-149.
15. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990;1049:99-125.
16. Inglis SC, McGeoch DJ, Mahy BW. Polypeptides specified by the influenza virus genoma. 2. Assignment of protein coding functions to individual genome segments by in vitro translation. Virology 1977;78:522-536.
17. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci U S A 1977;74:4370-4374.
18. Minshull J, Hunt T. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res 1986;14: 6433-6451.
19. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988;85:5011-5015.
20. Shuttleworth J, Matthews G, Dale L, Baker C, Colman A. Antisense oligodeoxyribonucleotide-directed cleavage of maternal mRNA in Xenopus oocytes and embryos. Gene 1988;72:267-275.
21. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM. Single base discrimination for ribonuclease II-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res 1995;23:954-961.
22. Frank P, Albert S, Cazenave C, Toulme JJ. Purification and characterization of human ribonuclease HII. Nucleic Acids Res 1994;22:5247-5254.
23. Donis Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res 1979;7:179-192.
24. Woolf TM, Melton DA, Jennings CG. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A 1992;89:7305-7309.
25. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. New York and London: Garland Publishing, Inc, 1994.
26. Benson DA, Boguski M, Lipman DJ, Ostell J. GenBank. Nucleic Acids Res 1996;24:1-5.
27. Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, Yap PL, et al. Variation of the hepatitis C virus 5′ non-coding region: implications for secondary structure, virus detection and typing. J Gen Virol 1995;76:1749-1761.
28. Choo QL, Richman KH, Han JL, Berger K, Lee C, Dong C, Gallegos C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991;88:2451-2455.
29. Furdon PJ, Dominski Z, Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res 1989;17:9193-9204.
30. Giles RV, Tidd DM. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res 1992;20:763-770.
31. Politz JC, Taneja KL, Singer RH. Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells. Nucleic Acids Res 1995;23:4946-4953.
32. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 1995;86:3891-3896.
33. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 1994;8:2156-2162.
34. Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 1995;9:118-130.
35. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994;4:67-69.
36. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
37. Ojwang J, Elbaggari A, Marshall HB, Jayaraman K, McGrath MS, Rando RF. Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine. J Acquir Immune Defic Syndr 1994;7:560-570.
38. Fennewald SM, Mustain S, Ojwang J, Rando RF. Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine. Antiviral Res 1995;26:37-54.
39. Marshall WS, Beaton G, Stein CA, Matsukura M, Caruthers MH. Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine. Proc Natl Acad Sci U S A 1992;89:6265-6269.
40. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. J Med Chem 1993;36:1923-1937.
41. Joyce GF. Amplification, mutation and selection of catalytic RNA. Gene 1989;82:83-87.
42. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822.
43. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249:505-510.
44. Klug SJ, Famulok M. All you wanted to know about SELEX. Mol Biol Rep 1994;20:97-107.
45. Heidenreich O, Pieken W, Eckstein F. Chemically modified RNA: approaches and applications. FASEB J 1993;7:90-96.
46. Touchette N. Gene therapy: not ready for prime time. Nat Med 1996;2: 7-8.
47. Olson KE, Higgs S, Gaines PJ, Powers AM, Davis BS, Kamrud KI, Carlson JO, et al. Genetically engineered resistance to dengue-2 virus transmission in mosquitoes. Science 1996;272:884-886.
48. Bachellerie JP, Michot B, Nicoloso M, Balakin A, Ni J, Fournier MJ. Antisense snoRNAs: a family of nucleolar RNAs with long complementarities to rRNA. Trends Biochem Sci 1995;20:261-264.
49. Elela SA, Igel H, Ares M. RNase III cleaves eukaryotic preribosomal RNA at a U3 snoRNP-dependent site. Cell 1996;85:115-124.
50. Robertson HD, Webster RE, Zinder ND. Purification and properties of ribonuclease III from Escherichia coli. J Biol Chem 1968;243:82-91.
51. Baglioni C. Interferon-induced enzymatic activities and their role in the antriviral state. Cell 1979;17:255-264.
52. Bass BL, Weintraub H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 1988;55:1089-1098.
53. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. HEPATOLOGY 1996;23:909-916.
54. Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995;210: 508-511.
55. Rebagliati MR, Melton DA. Antisense RNA injections in fertilized frog eggs reveal an RNA duplex unwinding activity. Cell 1987;48:599-605.
56. Bass BL, Weintraub H. A developmentally regulated activity that unwinds RNA duplexes. Cell 1987;48:607-613.
57. Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996;380:454-456.
58. Samuel CE. Interferon-induced proteins and their mechanisms of action. Hokkaido Igaku Zasshi 1994;69:1339-1347.
59. Baglioni C, Nilsen TW. The action of interferon at the molecular level. Am Sci 1981;69:392-399.
60. Desai SY, Patel RC, Sen GC, Malhotra P, Ghadge GD, Thimmapaya B. Activation of interferon-inducible 2′p-5′ oligoadenylate synthetase by adenoviral VAI RNA. J Biol Chem 1995;270:3454-3461.
61. Manche L, Green SR, Schmedt C, Mathews MB. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 1992;12:5238-5248.
62. Samuel CE. The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. J Biol Chem 1993;268:7603-7606.
63. Proud CG. PKR: a new name and new roles. Trends Biochem Sci 1995; 20:241-246.
64. Offermann MK, Zimring J, Mellits KH, Hagan MK, Shaw R, Medford RM, Mathews MB, et al. Activation of the double-stranded-RNA-activated protein kinase and induction of vascular cell adhesion molecule-1 by poly (I),poly (C) in endothelial cells. Eur J Biochem 1995;232:28-36.
65. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci U S A 1994;91:6288-6292.
66. Du W, Thanos D, Maniatis T. Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements. Cell 1993;74:887-898.
67. Hovanessian AG. The double stranded RNA-activated protein kinase induced by interferon: dsRNA-PK. J Interferon Cytokine Res 1989;9:641-647.
68. Kim SK, Wold BJ. Stable reduction of thymidine kinase activity in cells expressing high levels of anti-sense RNA. Cell 1985;42:129-138.
69. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990;2:279-289.
70. van der Krol, AR, Mur LA, Beld M, Mol JN, Stuitje AR. Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 1990;2:291-299.
71. Dawson WO. Gene silencing and virus resistance: a common mechanism. Trends in Plant Science 1996;1:107-108.
72. Dougherty WG, Parks TD. Transgenes and gene suppression: telling us something new? Curr Opin Cell Biol 1995;7:399-405.
73. Cameron FH, Jennings PA. Inhibition of gene expression by a short sense fragment. Nucleic Acids Res 1991;19:469-475.
74. Sheehy RE, Kramer M, Hiatt WR. Reduction of polygalacturonase activity in tomato fruit by antisense RNA. Proc Natl Acad Sci U S A 1988;85: 8805-8809.
75. Fox JL. FDA nears approval of Calgene's Flavr Savr. Biotechnology 1994; 12:439.
76. Grierson D. Silent genes and everlasting fruits and vegetables? Nature Biotechnology 1996;14:828.
77. Ayub R, Guis M, Amor M Ben, Gillot L, Rouston J-P, Latche A, Bouzayen M, et al. Expression of ACC oxidase antisense gene inhibits ripening of cantaloupe melon fruits. Nature Biotechnology 1996;14:862-866.
78. Steitz JA. Splicing takes a holiday. Science 1992;257:888-889.
79. Guerrier Takada C, Gardiner K, Marsh T, Pace N, Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983; 35:849-857.
80. Eguchi Y, Itoh T, Tomizawa J. Antisense RNA. Annu Rev Biochem 1991; 60:631-652.
81. Perelson AS, Brendel V. Kinetics of complementary RNA-RNA interaction involved in plasmid ColE1 copy number control. J Mol Biol 1989; 208:245-255.
82. Tomizawa J. Control of ColE1 plasmid replication. Intermediates in the binding of RNA I and RNA II. J Mol Biol 1990;212:683-694.
83. Hjalt TA, Wagner EG. Bulged-out nucleotides in an antisense RNA are required for rapid target RNA binding in vitro and inhibition in vivo. Nucleic Acids Res 1995;23:580-587.
84. Rittner K, Burmester C, Sczakiel G. In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1. Nucleic Acids Res 1993;21:1381-1387.
85. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BR, et al. Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 1994;265:789-792.
86. Lockard RE, Currey K, Browner M, Lawrence C, Maizel J. Secondary structure model for mouse beta Maj globin mRNA derived from enzymatic digestion data, comparative sequence and computer analysis. Nucleic Acids Res 1986;14:5827-5841.
87. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982;31:147-157.
88. Cech TR. Ribozymes and their medical implications. JAMA 1988;260: 3030-3034.
89. Barinaga M. Ribozymes: killing the messenger. Science 1993;262:1512-1514.
90. Altman S. RNA enzyme-directed gene therapy. Proc Natl Acad Sci U S A 1993;90:10898-10900.
91. Breaker RR, Joyce GF. Inventing and improving ribozyme function: rational design versus iterative selection methods. Trends Biotechnol 1994; 12:268-275.
92. Poeschla E, Staal F Wong. Antiviral and anticancer ribozymes. Curr Opin Oncol 1994;6:601-606.
93. Lehninger AL, Nelson DL, Cox MM. Principles of biochemistry. New York: Worth Publishers, 1993.
94. Noller HF, Hoffarth V, Zimniak L. Unusual resistance of peptidyl transferase to protein extraction procedures. Science 1992;256:1416-1419.
95. Pley HW, Flaherty KM, McKay DB. Three-dimensional structure of a hammerhead ribozyme. Nature 1994;372:68-74.
96. Cech TR, Uhlenbeck OC. Ribozymes. Hammerhead nailed down. Nature 1994;372:39-40.
97. Prody GA, Bakos JT, Buzayan JM, Schneider IR, Bruening G. Autocatalytic processing of dimeric plant virus satellite RNA. Science 1986;231: 1577-1580.
98. Hutchins CJ, Rathjen PD, Forster AC, Symons RH. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res 1986;14:3627-3640.
99. Forster AC, Symons RH. Self-cleavage of virusoid RNA is performed by proposed 55-nucleotide active site. Cell 1987;50:9-16.
100. Feldstein PA, Buzayan JM, Bruening G. Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA. Gene 1989;82:53-61.
101. Hampel A, Tritz R, Hicks M, Cruz P. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res 1990;18:299-304.
102. Sharmeen L, Kuo MY, Gottlieb G Dinter, Taylor J. Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol 1988; 62: 2674-2679.
103. Kuo MY, Sharmeen L, Gottlieb G Dinter, Taylor J. Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol 1988;62:4439-4444.
104. Chen PJ, Kalpana G, Goldberg J, Mason W, Werner B, Gerin J, Taylor J. Structure and replication of the genome of the hepatitis delta virus. Proc Natl Acad Sci U S A 1986;83:8774-8778.
105. Branch AD, Robertson HD. A replication cycle for viroids and other small infectious RNA's. Science 1984;223:450-455.
106. Branch AD, Levine BJ, Robertson HD. The brotherhood of circular RNA pathogens: viroids, circular satellites, and the delta agent. Semin Virol 1990;1:143-152.
107. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci U S A 1991;88:6921-6925.
108. Bertrand E, Pictet R, Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res 1994;22:293-300.
109. Werner M, Uhlenbeck OC. The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis. Nucleic Acids Res 1995;23:2092-2096.
110. Dropulic B, Jeang KT. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. Hum Gene Ther 1994;5:927-939.
111. Rich A, RajBhandary UL. Transfer RNA: molecular structure, sequence, and properties. Annu Rev Biochem 1976;45:805-860.
112. Ladner JE, Jack A, Robertus JD, Brown RS, Rhodes D, Clark BF, Klug A. Structure of yeast phenylalanine transfer RNA at 2.5 A resolution. Proc Natl Acad Sci U S A 1975;72:4414-4418.
113. Green MR. RNA bent for recognition. Gene Control 1991;1:245-247.
114. Ellington AD. Out of shape but fit for recognition. Current Biology 1993; 3:375-377.
115. Shen LX, Cai Z, Tinoco IJ. RNA structure at high resolution. FASEB J 1995;9:1023-1033.
116. Quigley GJ, Rich A. Structural domains of transfer RNA molecules. Science 1976;194:796-806.
117. Dutton MB. The scorpion and the tortoise. In: The tortoise and the geese and other fables of Bidpai. Boston: Houghton Mifflin Company, 1908:12-13.
118. Das S, Coward P, Dasgupta A. A small yeast RNA selectively inhibits internal initiation of translation programmed by poliovirus RNA: specific interaction with cellular proteins that bind to the viral 5′-untranslated region. J Virol 1994;68:7200-7211.
119. Trono D, Andino R, Baltimore D. An RNA sequence of hundreds of nucleotides at the 5′ end of poliovirus RNA is involved in allowing viral protein synthesis. J Virol 1988;62:2291-2299.
120. Jackson RJ, Howell MT, Kaminski A. The novel mechanism of initiation of picornavirus RNA translation. Trends Biochem Sci 1990;15:477-483.
121. Le SY, Chen JH, Sonenberg N, Maizel JVJ. Conserved tertiary structural elements in the 5′ nontranslated region of cardiovirus, aphthovirus and hepatitis A virus RNAs. Nucleic Acids Res 1993;21:2445-2451.
122. Glass MJ, Jia XY, Summers DF. Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5′ noncoding region. Virology 1993;193:842-852.
123. Brown EA, Zhang H, Ping LH, Lemon SM. Secondary structure of the 5′ nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 1992;20:5041-5045.
124. Tsukiyama Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol 1992;66:1476-1483.
125. Wang C, Sarnow P, Siddiqui A. A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA. J Virol 1994;68:7301-7307.
126. Oh SK, Sarnow P. Gene regulation: translational initiation by internal ribosome binding. Curr Opin Genet Dev 1993;3:295-300.
127. Joyce GF. In vitro evolution of nucleic acids. Curr Opin Struct Biol 1994; 4:331-336.
128. Chen H, Gold L. Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and RNase H activity. Biochemistry 1994;33:8746-8756.
129. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987;327:389-394.
130. Wank H, Rogers J, Davies J, Schroeder R. Peptide antibiotics of the tuberactinomycin family as inhibitors of group I intron RNA splicing. J Mol Biol 1994;236:1001-1010.
131. Gravel M, Melancon P, Gingras L Brakier. Cross-linking of streptomycin to the 16S ribosomal RNA of Escherichia coli. Biochemistry 1987;26: 6227-6232.
132. Zapp ML, Stern S, Green MR. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 1993;74:969-978.
133. Sande MA, Mandell GL. Antimicrobial agents. In: Gilman A Goodman, Rall TW, Nies AS, and Taylor P, eds. The Pharmacological basis of therapeutics. New York: McGraw-Hill, 1990:1098-1116.
134. Wang C, Sarnow P, Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol 1993;67:3338-3344.
135. Vella S. HIV therapy advances. Update on a proteinase inhibitor. AIDS 1994;8(suppl3):S25-S29.
136. Cohen J. Protease inhibitors: a tale of two companies. Science 1996;272: 1882-1883.